0026-895X/04/6504-832-841$20.00
Mol Pharmacol 65:832-841, 2004
Src and Cas Are Essentially but Differentially Involved in Angiotensin II-Stimulated Migration of Vascular Smooth Muscle Cells via Extracellular Signal-Regulated Kinase 1/2 and c-Jun NH2-Terminal Kinase Activation
Moe Kyaw,
Masanori Yoshizumi,
Koichiro Tsuchiya,
Shoji Kagami,
Yuki Izawa,
Yoshiko Fujita,
Nermin Ali,
Yasuhisa Kanematsu,
Kazunori Toida,
Kazunori Ishimura, and
Toshiaki Tamaki
Departments of Pharmacology (M.K., K.T., Y.I., Y.F., N.A., Y.K., T.T.), Pediatrics (S.K.), and Anatomy and Cell Biology (K.T., K.I.), The University of Tokushima School of Medicine, Tokushima, Japan
Angiotensin II (Ang II) plays an important role in several cardiovascular diseases associated with vascular smooth muscle cell (VSMC) growth and migration. Src activity is known to be required for the migration of a number of cell types. p130Cas was reported to be essential for cell migration and actin filament reorganization. Mitogen-activated protein (MAP) kinases were also reported to be critical regulatory factors for growth and migration of VSMC. However, precise intracellular mechanisms involving c-Src, p130Cas, and MAP kinases in Ang II-stimulated migration of VSMC have not been well elucidated. Here we demonstrated that Ang II rapidly and significantly stimulated tyrosine phosphorylation of Src and Cas and their association in rat aortic smooth muscle cells (RASMC). Ang II-stimulated tyrosine phosphorylation of Src and Cas and activation of ERK1/2 and JNK, but not p38, were potently inhibited by Src family tyrosine kinase inhibitors, herbimycin A (HA) and PP2. Ang II-stimulated Src and Cas association, tyrosine phosphorylation of Cas, and activation of ERK1/2 and JNK were suppressed in kinase-inactive Src (KI Src)-overexpressed RASMC. Ang II-stimulated JNK activation but not ERK1/2 activation was blocked in substrate domain-deleted Cas (
SD Cas)-overexpressed RASMC. In addition, HA, PP2, ERK1/2 inhibitor, 2'-amino-3'-methoxyflavone (PD98059) and JNK inhibitor, and anthra[1,9-cd]pyrazol-6(2H)-one (SP600125) significantly inhibited Ang II-stimulated migration of RASMC. Ang II-induced colocalization of Src and Cas and migration were inhibited in both KI Src- and
SD Cas-overexpressed RASMC. These findings suggest that Src and Cas are essentially but differentially involved in Ang II-stimulated migration of VSMC through the activation of ERK1/2 and JNK.
Received October 17, 2003;
accepted December 5, 2003
Address correspondence to: Masanori Yoshizumi, M.D., Ph.D., Department of Pharmacology, The University of Tokushima School of Medicine, 3-18-15 Kuramoto, Tokushima 770-8503, Japan. E-mail: yoshizu{at}basic.med.tokushima-u.ac.jp
This article has been cited by other articles:

|
 |

|
 |
 
K. Schroder, I. Helmcke, K. Palfi, K.-H. Krause, R. Busse, and R. P. Brandes
Nox1 Mediates Basic Fibroblast Growth Factor-Induced Migration of Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2007;
27(8):
1736 - 1743.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Liu, T. Shimosawa, H. Matsui, F. Meng, S. C. Supowit, D. J. DiPette, K. Ando, and T. Fujita
Adrenomedullin inhibits angiotensin II-induced oxidative stress via Csk-mediated inhibition of Src activity
Am J Physiol Heart Circ Physiol,
April 1, 2007;
292(4):
H1714 - H1721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ogden, J. M. Thompson, Z. Hickner, T. Huang, D. D. Tang, and S. W. Watts
A new signaling paradigm for serotonin: use of Crk-associated substrate in arterial contraction
Am J Physiol Heart Circ Physiol,
December 1, 2006;
291(6):
H2857 - H2863.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Ohtsu, H. Suzuki, H. Nakashima, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi
Angiotensin II Signal Transduction Through Small GTP-Binding Proteins: Mechanism and Significance in Vascular Smooth Muscle Cells
Hypertension,
October 1, 2006;
48(4):
534 - 540.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Hunyady and K. J. Catt
Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II
Mol. Endocrinol.,
May 1, 2006;
20(5):
953 - 970.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Fujita, M. Yoshizumi, Y. Izawa, N. Ali, H. Ohnishi, Y. Kanematsu, K. Ishizawa, K. Tsuchiya, and T. Tamaki
Transactivation of Fetal Liver Kinase-1/Kinase-Insert Domain-Containing Receptor by Lysophosphatidylcholine Induces Vascular Endothelial Cell Proliferation
Endocrinology,
March 1, 2006;
147(3):
1377 - 1385.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ishizawa, Y. Izawa, H. Ito, C. Miki, K. Miyata, Y. Fujita, Y. Kanematsu, K. Tsuchiya, T. Tamaki, A. Nishiyama, et al.
Aldosterone Stimulates Vascular Smooth Muscle Cell Proliferation Via Big Mitogen-Activated Protein Kinase 1 Activation
Hypertension,
October 1, 2005;
46(4):
1046 - 1052.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Ohtsu, M. Mifune, G. D. Frank, S. Saito, T. Inagami, S. Kim-Mitsuyama, Y. Takuwa, T. Sasaki, J. D. Rothstein, H. Suzuki, et al.
Signal-Crosstalk Between Rho/ROCK and c-Jun NH2-Terminal Kinase Mediates Migration of Vascular Smooth Muscle Cells Stimulated by Angiotensin II
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2005;
25(9):
1831 - 1836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Zhang, G. Ding, S. Huang, Y. Wu, X. Pan, X. Guan, R. Chen, and T. Yang
c-Jun NH2-terminal kinase mediation of angiotensin II-induced proliferation of human mesangial cells
Am J Physiol Renal Physiol,
June 1, 2005;
288(6):
F1118 - F1124.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Nishiyama, L. Yao, Y. Fan, M. Kyaw, N. Kataoka, K. Hashimoto, Y. Nagai, E. Nakamura, M. Yoshizumi, T. Shokoji, et al.
Involvement of Aldosterone and Mineralocorticoid Receptors in Rat Mesangial Cell Proliferation and Deformability
Hypertension,
April 1, 2005;
45(4):
710 - 716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Natarajan, G. Yin, and B. C. Berk
Scaffolds Direct Src-Specific Signaling in Response to Angiotensin II: New Roles for Cas and GIT1
Mol. Pharmacol.,
April 1, 2004;
65(4):
822 - 825.
[Full Text]
|
 |
|
Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics